Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mylan NV Ord Shs (MYL)

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,744,591
  • Shares Outstanding, K 516,133
  • Annual Sales, $ 11,434 M
  • Annual Income, $ 352,500 K
  • 60-Month Beta 1.71
  • Price/Sales 0.84
  • Price/Cash Flow 2.14
  • Price/Book 0.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 1.29
  • Number of Estimates 6
  • High Estimate 1.32
  • Low Estimate 1.27
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -0.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.79 +11.55%
on 11/08/19
19.07 -1.78%
on 12/05/19
+0.94 (+5.28%)
since 11/05/19
3-Month
16.79 +11.55%
on 11/08/19
22.90 -18.21%
on 09/13/19
-1.49 (-7.37%)
since 09/05/19
52-Week
16.63 +12.63%
on 05/31/19
32.69 -42.70%
on 12/06/18
-14.23 (-43.17%)
since 12/04/18

Most Recent Stories

More News
Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

RHHBY : 38.4500 (-0.18%)
PFE : 37.89 (-0.66%)
TEVA : 9.97 (-3.58%)
MYL : 18.79 (-0.48%)
Acorda (ACOR) Down More Than 80% Year to Date: Here's Why

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.

ACOR : 1.73 (-5.46%)
VRTX : 222.44 (-0.66%)
ANIK : 57.18 (+0.21%)
MYL : 18.79 (-0.48%)
Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri(TM) (trastuzumab-dkst), in the U.S.

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the U.S. launch of Ogivri(TM) (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab). Ogivri is available...

MYL : 18.79 (-0.48%)
Relatively Good Performance Detected in Shares of Mylan Nv in the Pharmaceuticals Industry (MYL , COLL , BMY , NKTR , PRGO )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

BMY : 59.37 (+0.80%)
COLL : 20.87 (+1.07%)
MYL : 18.79 (-0.48%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Merck & Co (MRK , MYL , ZTS , BMY , PRGO )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

MRK : 88.35 (-0.36%)
MYL : 18.79 (-0.48%)
ZTS : 119.60 (-0.12%)
Mylan Nv Set to Possibly Pullback After Yesterday's Rally of 3.23%

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $17.50 to a high of $17.90. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $17.65...

MYL : 18.79 (-0.48%)
Mylan to Present at the Evercore ISI HealthCONx Conference

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will present at the Evercore ISI HealthCONx Conference in Boston on Tuesday, Dec. 3, 2019 at 11 a.m. ET.

MYL : 18.79 (-0.48%)
Downtrend Call Working As Mylan Nv Stock Falls 6.0% (MYL)

SmarTrend identified a Downtrend for Mylan Nv (NASDAQ:MYL) on October 2nd, 2019 at $18.45. In approximately 2 months, Mylan Nv has returned 6.02% as of today's recent price of $17.34.

MYL : 18.79 (-0.48%)
After Yesterday's Decline of 1.04%, Mylan Nv Offers Investors Better Value

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $17.03 to a high of $17.28. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $17.06 on...

MYL : 18.79 (-0.48%)
Look for Shares of Mylan Nv to Potentially Rebound after Yesterday's 1.04% Sell Off

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $17.03 to a high of $17.28. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $17.06 on...

MYL : 18.79 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MYL with:

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 19.27
1st Resistance Point 19.08
Last Price 18.79
1st Support Level 18.61
2nd Support Level 18.33

See More

52-Week High 32.69
Fibonacci 61.8% 26.56
Fibonacci 50% 24.66
Fibonacci 38.2% 22.76
Last Price 18.79
52-Week Low 16.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar